Evotec SE (EVO)
| Bid | 2.7 |
| Market Cap | 2.55B |
| Revenue (ttm) | 777.05M |
| Net Income (ttm) | -171.37M |
| EPS (ttm) | -0.53 |
| PE Ratio (ttm) | -6.78 |
| Forward PE | -335.5 |
| Analyst | Hold |
| Ask | 4.62 |
| Volume | 487,335 |
| Avg. Volume (20D) | 73,549 |
| Open | 3.75 |
| Previous Close | 3.27 |
| Day's Range | 3.59 - 3.75 |
| 52-Week Range | 2.84 - 7.77 |
| Beta | 1.09 |
About EVO
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly;...
Analyst Forecast
According to 2 analyst ratings, the average rating for EVO stock is "Hold." The 12-month stock price forecast is $5.9, which is an increase of 64.12% from the latest price.
Stock Forecasts
5 hours ago · accessnewswire.com
Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 ResultsEvotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth Strategy builds on technology and science leadership, focusing on high-growth, high-value ...
1 week ago · accessnewswire.com
Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025HAMBURG, DE / ACCESS Newswire / April 10, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2024 on Thursday, 17 Ap...
1 month ago · accessnewswire.com
Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers SquibbOngoing strategic partnership advances joint pipeline in neurodegeneration research Evotec receives a $20 million payment to further progress research HAMBURG, DE / ACCESS Newswire / March 4, 2025 / E...
